Medical News

RSS

Eye implant restores some vision in retinitis pigmentosa

According to a new scientific breakthrough, a device - a tiny, three-by-three millimetre microchip, has allowed patients with inherited blindness to detect objects with their eyes, unlike a rival approach that uses an external camera. The procedure details are outlined in the journal Proceedings of the Royal Society B.

3 Nov 2010

One-third of breast cancer survivors rate breast-conserving treatments as fair

A third of breast cancer survivors who received the breast-conserving treatments lumpectomy and radiation rate the appearance of their post-treatment breast as only "fair" or "poor" in comparison to their untreated breast, according to a new University of Pennsylvania School of Medicine study that will be presented today at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.

3 Nov 2010

Vanda third quarter total revenue increases to $7.2 million

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the third quarter and nine months ended September 30, 2010.

3 Nov 2010

Bortezomib reduces inflammation and promotes bone healing in arthritis models

A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

3 Nov 2010

Insmed third quarter total revenues decrease to $1.8 million

Insmed Inc., a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2010.

3 Nov 2010

ADVENTRX submits NDA for Exelbine to FDA

ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine.

3 Nov 2010

BioClinica third quarter service revenues increase to $15.8 million

BioClinica®, Inc., a global provider of clinical trial management services, today announced its financial results for the three and nine months ended September 30, 2010.

From Clario 3 Nov 2010

First Edition: November 3, 2010

Today's headlines track the GOP's sweeping electoral gains and begin to explore what this power shift might mean for the future of the health law.

3 Nov 2010

Cambridge Heart third quarter sales increase 21% to $793,000

Cambridge Heart, Inc., today reported results for the three and nine months ended September 30, 2010.

3 Nov 2010

Revolutions Medical announces completion of designs for 5ml and 10ml fixed needle RevVac Safety Syringes

Revolutions Medical Corporation announced today that due to the launch of its 3ml RevVac Safety SyringeTM during the Medica show in Dusseldorf, Germany and the enormous interest that the launch has received from healthcare professionals and corporations in Europe, the company will host an additional reception in London on Saturday, November 20th from 7:30 PM - 9:30 PM at the Landmark Hotel, Tower Suite.

3 Nov 2010

Top 10 Medical Innovations for 2011

From pill-sized cameras to radioactive compounds that let doctors "see" inside a patient's brain, Cleveland Clinic's Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases.

3 Nov 2010

MGH implements Mobile Aspects' RFID enabled supply automation system

Mobile Aspects announced today that Massachusetts General Hospital (MGH) has fully implemented its radio frequency identification (RFID) enabled supply automation system to store, track, and manage medical devices and supplies used for neuro interventional procedures in the IR division within the Department of Radiology.

3 Nov 2010

Ingenuity Systems and Geospiza partner to enable seamless next-generation sequencing analysis workflow

Ingenuity® Systems, a leading provider of information solutions for life science researchers, and Geospiza, Inc., the market leading developer of laboratory management and genetic analysis software, today announced a collaboration to enable a seamless next-generation sequencing analysis workflow. The companies will integrate their software products, GeneSifter® and IPA®, to enable researchers to obtain deep biological insights from their project samples through a rapid and reliable workflow to analyze and visualize next-generation sequencing data.

3 Nov 2010

Fibrocell, Meifu to develop and market autologous fibroblast therapies in Asia

Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.

3 Nov 2010

Questcor announces launch of H.P. Acthar Gel for infantile spasms

Questcor Pharmaceuticals, Inc. today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010.

3 Nov 2010

GTx receives $1.2 million under QTDP program

GTx, Inc. announced that the company has been awarded approximately $1.2 million by the United States Government under the Qualifying Therapeutic Discovery Project Program (QTDP), a $1 billion fund established under HR: 3590 Patient Protection and Affordable Care Act.

3 Nov 2010

PDI third quarter revenue increases 83% to $36.0 million

PDI, Inc., today reported financial and operational results for the third quarter ended September 30, 2010.

3 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

IDEV receives FDA marketing clearance for SUPERA VERITAS Transhepatic Biliary System

IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance to market the SUPERA VERITAS Transhepatic Biliary System.

3 Nov 2010

Harvard Bioscience third quarter revenue increases 26.0% to $26.5 million

Harvard Bioscience, Inc. a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial highlights for the three and nine months ended September 30, 2010.

From Harvard Bioscience 3 Nov 2010